Stock AnalizRevolution Medicines, Inc. RVMD
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Revolution Medicines, Inc. (RVMD) is a healthcare company listed in the US with a market value of about $37.3B. In the twelve months to September 30, 2026 it had revenue of $198M and net income of -$1.9B, a net margin of -946.8%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -36%.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $198M | $0 | $0 | $12M | $35M | $29M | $43M | $50M | $20M |
| Net income | -$1.9B | -$1.1B | -$600M | -$436M | -$249M | -$187M | -$108M | -$48M | -$42M |
| Free cash flow | -$1.4B | -$914M | -$568M | -$358M | -$235M | -$154M | -$103M | -$52M | -$286000 |
| EPS (diluted) | $-9.14 | $-5.95 | $-3.58 | $-3.86 | $-3.08 | $-2.57 | $-2.01 | $-22.33 | $-21.24 |
| Net margin | -946.8% | — | — | -3768.3% | -702.9% | -636.6% | -251.6% | -95.2% | -207.2% |
| ROIC | — | -66.0% | -28.7% | -25.2% | -34.4% | -28.1% | -21.7% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 24 analysts is $274.84, 60% above the current price; targets range from $179.00 to $350.00; the consensus rating is “Strong buy”; expected EPS is $-8.30 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Revolution Medicines pay a dividend?
Not currently.
Is Revolution Medicines a good stock to buy?
We do not give buy or sell advice. Revolution Medicines scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.